Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

133 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Anti-PD-1 Autoantibody Predicts Survival of Patients With Hepatocellular Carcinoma Receiving Atezolizumab/Bevacizumab.
Sasaki Y, Matsumoto K, Takaki A, Adachi T, Takahara M, Ozato K, Takeuchi Y, Sue M, Miyake N, Wada N, Onishi H, Shiraha H, Oda T, Tsutsumi K, Nouso K, Kariyama K, Hagihara H, Moriya A, Otsuka M. Sasaki Y, et al. Among authors: shiraha h. Gastro Hep Adv. 2024 Aug 2;3(8):1138-1147. doi: 10.1016/j.gastha.2024.07.018. eCollection 2024. Gastro Hep Adv. 2024. PMID: 39559295 Free PMC article.
Can early precut reduce post-endoscopic retrograde cholangiopancreatography pancreatitis in patients with difficult bile duct cannulation?
Tanikawa T, Miyake K, Kawada M, Ishii K, Fushimi T, Urata N, Wada N, Nishino K, Suehiro M, Kawanaka M, Shiraha H, Haruma K, Kawamoto H. Tanikawa T, et al. Among authors: shiraha h. World J Gastrointest Endosc. 2024 Sep 16;16(9):519-525. doi: 10.4253/wjge.v16.i9.519. World J Gastrointest Endosc. 2024. PMID: 39351176 Free PMC article.
Response to the letter: "Predictive factors for transition to conversion therapy in HCC using atezolizumab plus bevacizumab".
Kikuchi T, Takeuchi Y, Nouso K, Kariyama K, Kuwaki K, Toshimori J, Iwado S, Moriya A, Hagihara H, Takabatake H, Tada T, Yasunaka T, Sakata M, Sue M, Miyake N, Adachi T, Wada N, Onishi H, Shiraha H, Takaki A, Otsuka M. Kikuchi T, et al. Among authors: shiraha h. Liver Int. 2024 Jul;44(7):1736-1737. doi: 10.1111/liv.15964. Epub 2024 May 8. Liver Int. 2024. PMID: 38717049 No abstract available.
Predictive factors for transition to conversion therapy in hepatocellular carcinoma using atezolizumab plus bevacizumab.
Kikuchi T, Takeuchi Y, Nouso K, Kariyama K, Kuwaki K, Toshimori J, Iwado S, Moriya A, Hagihara H, Takabatake H, Tada T, Yasunaka T, Sakata M, Sue M, Miyake N, Adachi T, Wada N, Onishi H, Shiraha H, Takaki A, Otsuka M. Kikuchi T, et al. Among authors: shiraha h. Liver Int. 2024 Jun;44(6):1456-1463. doi: 10.1111/liv.15907. Epub 2024 Mar 15. Liver Int. 2024. PMID: 38488749
The prediction of early progressive disease in patients with hepatocellular carcinoma receiving atezolizumab plus bevacizumab.
Takeuchi Y, Nouso K, Fujioka SI, Kariyama K, Kobashi H, Uematsu S, Moriya A, Hagihara H, Takabatake H, Nakamura S, Yabushita K, Kikuchi T, Oyama A, Adachi T, Wada N, Onishi H, Shiraha H, Takaki A. Takeuchi Y, et al. Among authors: shiraha h. Cancer Med. 2023 Sep;12(17):17559-17568. doi: 10.1002/cam4.6369. Epub 2023 Aug 3. Cancer Med. 2023. PMID: 37537956 Free PMC article.
Study Protocol for a Trial: A Single-Arm, Open-Labeled Study Evaluating Transcatheter Arterial Embolization Plus Everolimus Combination Therapy for Patients With Liver Metastasis of Gastroenteropancreatic Neuroendocrine Tumors.
Takeuchi Y, Kato H, Horiguchi S, Oyama A, Adachi T, Wada N, Onishi H, Shiraha H, Takaki A. Takeuchi Y, et al. Among authors: shiraha h. Clin Med Insights Oncol. 2022 Nov 6;16:11795549221127750. doi: 10.1177/11795549221127750. eCollection 2022. Clin Med Insights Oncol. 2022. PMID: 36387610 Free PMC article.
133 results